Target intelligence / Profile preview

Japanese encephalitis virus non-structural protein 3 (NS3) (JEV NS3)

Target
JEV NS3
Molecular classification
Enzyme, Serine protease, RNA helicase, NTPase, ATPase
01

Overview

JEV NS3 is a large, multifunctional protein of approximately 619 amino acids that is indispensable for the replication and pathogenesis of the Japanese encephalitis virus [1.1.1, 1.3.2]. It possesses two distinct enzymatic regions: an N-terminal serine protease domain and a C-terminal domain with RNA helicase and nucleoside triphosphatase (NTPase) activities [1.1.1, 1.2.1]. The protease domain, in complex with its essential cofactor NS2B, catalyzes the proteolytic processing of the viral polyprotein at specific junctions, which is a prerequisite for the assembly of the viral replication complex [1.1.2, 1.3.4]. The helicase domain utilizes energy from ATP hydrolysis to unwind double-stranded RNA intermediates, facilitating the synthesis of new viral genomes [1.1.1, 1.2.1]. Additionally, NS3 is involved in subverting host innate immunity and inducing neuronal apoptosis, which are key factors in the development of severe encephalitis [1.1.2, 1.4.3]. Due to its central role in the viral life cycle, NS3 is a major focus for the development of small-molecule inhibitors, including protease and helicase antagonists, aimed at treating JEV infections [1.2.2, 1.2.4].

Other names
Non-structural protein 3JEV NS3 proteaseJEV NS3 helicaseNS3 proteinSerine protease NS3Genome polyprotein NS3
02

Mechanism of action

Inhibition of the NS2B-NS3 serine protease activity to prevent polyprotein processing, or inhibition of the NS3 helicase/NTPase activity to block viral RNA unwinding and replication.

03

Biological functions

Viral replicationPolyprotein processingRNA unwindingATP hydrolysisImmune evasionApoptosis induction
04

Disease associations

InfectionJapanese encephalitisNeuroinflammationCentral nervous system disorder
05

Safety considerations

Emergence of drug-resistant viral mutantsPotential off-target inhibition of host cell proteases or helicasesDifficulty in achieving therapeutic concentrations across the blood-brain barrierRisk of neurotoxicity
06

Interacting drugs

Ivermectin

9 more in the full profile.

07

Biomarkers

Viral RNA loadNS3 protein levelsCaspase-3 activityCaspase-9 activityInterferon-alpha/beta levels

Beyond the preview

Go deeper on Japanese encephalitis virus non-structural protein 3 (NS3) (JEV NS3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Japanese encephalitis virus non-structural protein 3 (NS3) (JEV NS3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call